Topic: Gilead Sciences

The FBI and federal cybersecurity agents warned that hackers linked to the Chinese and Iranian governments were targeting U.S. universities and pharmaceutical companies to steal COVID-19 research. Assistant Attorney General John Demers stated that China is desperate to be the first to develop a vaccine for geopolitical prestige. Tensions escalated as President Trump suggested reporters "ask China" about the global death toll during a press briefing.

Investigative reporter Sharyl Attkisson released a report detailing the financial interests behind the transgender advocacy movement, identifying pharmaceutical companies as primary funders. The report highlights that Gilead Sciences, a major producer of HIV medications, and AbbVie, the manufacturer of the puberty-suppressing drug Lupron, are top donors to trans organizations. Critics argue this creates a "Transgender Leviathan" where medical profits drive social policy and pediatric healthcare decisions.

The United States has purchased virtually the entire global supply of Remdesivir for the next three months, totaling over 500,000 doses. The drug, which costs approximately $3,120 per patient, has replaced hydroxychloroquine as the preferred therapeutic in the public eye. The move is criticized as a "scam" driven by pharmaceutical interests rather than public health.

Clinical trials for Remdesivir showed a statistically significant but modest 32% reduction in recovery time for hospitalized COVID-19 patients. Dr. Fauci expressed optimism that drug combinations might provide an effective treatment bridge before a vaccine is widely available.

The FBI and federal cybersecurity agents issued a warning that hackers linked to the Chinese government are attempting to steal U.S. research on COVID-19 vaccines and treatments. Iran is also accused of targeting executives at Gilead Sciences, the maker of Remdesivir. The hosts also comment on the vocal condition of CBS correspondent Jeff Pegues during his reporting.

Dr. Anthony Fauci announced positive results from an NIAID trial of Gilead’s Remdesivir, noting a 31% improvement in recovery time for COVID-19 patients. The study showed recovery times dropping from 15 days to 11 days, which Fauci compared to the breakthrough of HIV drugs in the 1980s. The drug is expected to receive emergency use authorization from the FDA as a new standard of care.

Prior to the recent NIH success, Remdesivir faced negative press following a leaked video from the University of Chicago and reports on the health news site STAT. Initial interpretations of the data were considered disappointing, causing Gilead's stock to sink. Critics point out that the recovery time improvement now being celebrated was previously dismissed as statistically insignificant "office chatter."

The rapid promotion of Remdesivir mirrors the historical rollout of HIV treatments like Truvada, which was also developed by Gilead Sciences. Dr. Anthony Fauci and Dr. Deborah Birx have long-standing ties to Gilead through their decades of work on the HIV mission at the NIH. The current push for Remdesivir is seen by some as a pharmaceutical-heavy approach that favors hospital-administered IV treatments over cheaper, oral alternatives.

Mainstream news reports a surge in Gilead Sciences' stock price following claims that the drug Remdesivir helped COVID-19 patients in Chicago. The hosts contrast the enthusiastic media coverage of this expensive, patented drug with the dismissal of hydroxychloroquine as "snake oil." They argue that the media is prioritizing corporate pharmaceutical interests over generic therapeutic successes.

The segment addresses the media's portrayal of Dr. Anthony Fauci as a "foil" to President Trump. The hosts play a clip from a WMAL interview where Fauci expresses frustration with the media's attempts to create distance between him and the President. They also discuss Fauci's professional ties to the Gates Foundation and Gilead Sciences.

Dr. Fauci expresses optimism for Remdesivir, an antiviral drug developed by Gilead Sciences originally tested for Ebola. While Chloroquine is discussed as a cheaper alternative, concerns remain regarding its potential for liver damage, depression, and vivid dreams, necessitating frequent blood tests for patients.

The hosts analyze the stock performance of biotech companies like Moderna and Gilead Sciences following mentions by Larry Kudlow. They clarify that Gilead's drug, Remdesivir, is an antiviral treatment originally developed for Ebola, not a vaccine. They emphasize that a viable vaccine is likely at least 18 months away despite market hype.

Congress is investigating Dr. Raymond Shonazi, a VA doctor who made $400 million selling a Hepatitis C drug to Gilead Sciences while working for the government. The drug, which costs $1,000 per pill, is now unaffordable for the VA. The hosts discuss the "gangster" behavior of pharmaceutical CEOs and the corruption within the medical-industrial complex.

Gilead Sciences is facing controversy over its Hepatitis C drug, Sovaldi, which costs $84,000 for a course of treatment in the U.S. While the company is negotiating a deal to sell a generic version in 80 developing countries, American patients remain stuck with the high price tag. The hosts describe the situation as "disturbing and disgusting," noting the disparity in global drug pricing.

The World Health Organization and the FDA are criticized for promoting Truvada (PrEP) as a primary tool for HIV prevention. The hosts argue that the drug, manufactured exclusively by Gilead Sciences, is being marketed as a "license to bear back" while ignoring the necessity of safe sex practices and the high cost of the medication.

Gilead Sciences, the manufacturer of Truvada, faces scrutiny over the drug's $14,000 annual price tag and its potential inclusion in mandatory insurance coverage under the Affordable Care Act. While studies show varying efficacy rates, the drug is being positioned as a "vitamin-like" daily requirement for high-risk populations. The board of directors at Gilead includes individuals with ties to major insurance companies and Stanford University, suggesting a deeply entrenched corporate-political alliance.

Gilead Sciences' stock (GILD) saw a significant surge on the Nasdaq, doubling in value between January and July 2012, prior to the official FDA announcement regarding Truvada. This price action has led to allegations of insider trading by those aware of the impending approval. The aggressive push for Truvada is compared to the HPV vaccine mandates, with critics warning that long-term side effects or carcinogenic risks may eventually emerge.

An Indian company, Cipla, is reportedly preparing to flood the market with generic Tamiflu, which may explain Roche's urgency in selling existing stock. The hosts discuss the complexities of pharmaceutical patents and the practice of drug companies marketing against generic alternatives as the patent expiration date approaches.

Gilead Sciences, the developer of Tamiflu, reportedly terminated its agreement with Roche regarding marketing rights. The hosts also discuss blog reports claiming the swine flu virus shows signs of being engineered. They draw a parallel between biological viruses and the computer antivirus industry, suggesting companies may create problems to sell solutions.